12:00 AM
Jun 26, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

: Phase II

In SEPR's 900-patient dose ranging Phase II trial, (S)-oxybutynin significantly improved urinary frequency and urinary incontinence, and was well tolerated, SEPR said....

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >